MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

Core Insights - The interim results from the CAMPAIGN trial indicate that MIMEDX's EPIEFFECT product shows significant clinical benefits compared to standard of care (SOC) wound treatment [1][2][3] - The study published in the International Journal of Tissue Repair highlights a posterior probability of 98.5% for EPIEFFECT's superiority over SOC based on 71 enrolled patients [4] - MIMEDX's CEO expressed optimism regarding the favorable results and the potential for successful outcomes upon the study's completion [5] Study Details - The CAMPAIGN trial is a randomized controlled trial designed to evaluate EPIEFFECT against SOC for managing nonhealing diabetic foot ulcers [2][3] - Enrollment for the trial is ongoing, with an expanded sample set of 88 patients presented at the Tissue Research Evidence Summit [3] - The study's success criteria were defined as a posterior probability greater than 90% [4] Market Implications - The interim analysis results strengthen the case for Medicare and commercial insurance coverage for EPIEFFECT, especially with upcoming Local Coverage Determination implementations scheduled for January 1, 2026 [6] - MIMEDX aims to position EPIEFFECT favorably within the healthcare market through demonstrated clinical efficacy [6] Company Overview - MIMEDX is a leader in providing solutions for chronic and hard-to-heal wounds, with a vision to be the leading global provider of healing solutions [7]